CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00808509
NCT00808509Phase 4Completed
CompareCT.gov

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (ADMIRE)

AbbVie (prior sponsor, Abbott)·interventional·Posted Dec 16, 2008·Updated Dec 16, 2013

In Brief

A Phase 4 clinical trial evaluating adalimumab and methotrexate for Arthritis, Rheumatoid. Completed, enrolled 33 participants across 8 sites.

Detailed Summary

The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with methotrexate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesSweden
CollaboratorsPharma Consulting Group AB

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 16, 2008
Enrollment StartJan 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.5 years ago

Interventions

adalimumabbiological

40 mg every other week via subcutaneous injection

methotrexatedrug

At least 10 mg/week administered orally or subcutaneously